Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Children's Oncology Group
City of Hope Medical Center
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
Emory University
Eli Lilly and Company
St. Jude Children's Research Hospital
Medical University of Vienna
National Institutes of Health Clinical Center (CC)
Clinica Universidad de Navarra, Universidad de Navarra
M.D. Anderson Cancer Center